Overview
UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.
Work here?Claim your company
About UntilLabs
Industries
Company Size
51-200
Company Stage
Series A
Total Funding
$58M
Headquarters
San Francisco, California
Founded
2024
Get referred to UntilLabs
See people who can refer or advise you
Simplify's Take
What believers are saying
- 2026 hiring spans perfusion, cardiac biology, and organ perfusion, signaling active R&D expansion.
- Pig organ isolation and ex-vivo evaluation roles suggest near-term preclinical organ validation.
- The 2026 patent strengthens defensibility around cryoprotectants, vitrification, and rewarming hardware.
What critics are saying
- X-Therma already has FDA Breakthrough status and 120-hour kidney preservation claims.
- Until still has no public human transplant data, leaving commercialization unproven.
- Whole-body cryopreservation messaging invites regulatory scrutiny and distracts from organ preservation execution.
What makes UntilLabs unique
- Founders Fund, Lux, and Field backed Until Labs' 2025 $58M Series A.
- Until's 2026 site says it has raised $100M+ and is hiring.
- Its patent for reversible cryopreservation covers perfusion, pressure, and volumetric rewarming.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$58M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Paid Holidays
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Commuter Benefits
Professional Development Budget
Growth & Insights and Company News
6 month growth
3%1 year growth
3%2 year growth
11%Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.
This investment, led by Founders Fund with participation from Lux Capital and Field Ventures, brings total investment to date to $100M+, and will be used to build out the team and operational infrastructureSAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Until Labs announced today a Series A funding round of $58 million, led by Founders Fund with participation from Lux Capital and Field Ventures. The company develops perfusion hardware, cryoprotective agents, and rewarming infrastructure to rev
Fenwick represents Until Labs in $58M Series A funding.
UntilLabs is Hiring for 9 Jobs on Simplify!
Find jobs on Simplify and start your career today
About UntilLabs
Industries
Company Size
51-200
Company Stage
Series A
Total Funding
$58M
Headquarters
San Francisco, California
Founded
2024
UntilLabs is Hiring for 9 Jobs on Simplify!
Find jobs on Simplify and start your career today